Castle Biosciences (NASDAQ:CSTL) Insider Sells $150,938.06 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $24.29, for a total transaction of $150,938.06. Following the transaction, the insider directly owned 21,479 shares in the company, valued at approximately $521,724.91. This represents a 22.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of NASDAQ:CSTL opened at $23.64 on Thursday. The business has a 50-day moving average of $21.51 and a two-hundred day moving average of $28.24. The firm has a market capitalization of $717.00 million, a PE ratio of -53.73 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%.The business had revenue of $84.23 million during the quarter, compared to analysts’ expectations of $79.23 million. As a group, research analysts forecast that Castle Biosciences, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CSTL shares. Canaccord Genuity Group decreased their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. KeyCorp set a $35.00 price objective on Castle Biosciences in a research report on Friday, May 29th. BTIG Research reduced their price objective on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings downgraded Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Wall Street Zen lowered Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. purchased a new stake in Castle Biosciences during the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Castle Biosciences during the fourth quarter worth approximately $35,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after buying an additional 297 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Castle Biosciences by 140.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after buying an additional 1,022 shares during the last quarter. Finally, CWM LLC increased its stake in shares of Castle Biosciences by 20.5% in the fourth quarter. CWM LLC now owns 2,302 shares of the company’s stock worth $90,000 after buying an additional 391 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.